Summary for 9CD5
Entry DOI | 10.2210/pdb9cd5/pdb |
Descriptor | Fibroblast growth factor receptor 1, 1,2-ETHANEDIOL, (3P)-5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-3-{6-[6-(methanesulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl]pyridin-3-yl}-1H-indazole, ... (5 entities in total) |
Functional Keywords | kinase, transferase, inhibitor, cancer, achondroplasia, fgfr3, fgfr, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 2 |
Total formula weight | 72710.53 |
Authors | Hoffman, I.H.,Nelson, K.J.,Rideout, M.C.,Frye, C.,Bensen, D.C.,Hudkins, R.L. (deposition date: 2024-06-24, release date: 2024-09-25, Last modification date: 2024-10-02) |
Primary citation | Hudkins, R.L.,Allen, E.,Balcer, A.,Hoffman, I.D.,Iyer, S.,Neal, M.,Nelson, K.J.,Rideout, M.,Ye, Q.,Starrett, J.H.,Patel, P.,Harris, T.,Swanson, R.V.,Bensen, D.C. Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia. J.Med.Chem., 67:16737-16756, 2024 Cited by PubMed: 39258897DOI: 10.1021/acs.jmedchem.4c01531 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.939 Å) |
Structure validation
Download full validation report